Here are the key facts about Ozempic:
Ozempic is the brand name for semaglutide, a prescription GLP-1 receptor agonist. In Canada, Ozempic is listed as a once-weekly semaglutide injection for adults with type 2 diabetes. It is used with diet/exercise and sometimes with other diabetes medicines to improve blood sugar control. It is also indicated to reduce certain major cardiovascular and kidney risks in adults with type 2 diabetes who have established cardiovascular disease and/or chronic kidney disease.
It is not insulin and it is not for type 1 diabetes. The Canadian monograph says Ozempic is not a substitute for insulin and should not be used for type 1 diabetes or diabetic ketoacidosis.
It can cause weight loss, but Ozempic is not officially a weight-loss drug. The official Ozempic site says Ozempic may help people lose weight, but also states “Ozempic is not a weight-loss drug.” Semaglutide is used for chronic weight management under other branding/dosing, such as Wegovy.
How it works: semaglutide helps lower blood sugar by increasing insulin release when blood sugar is high, lowering glucagon, and slowing early stomach emptying after meals. The appetite/fullness effects and slower stomach emptying are why many people eat less and lose weight.
Typical injection dosing starts low. The Canadian monograph lists a starting dose of 0.25 mg once weekly, then usually 0.5 mg once weekly after 4 weeks; doses may be increased to 1 mg or 2 mg once weekly if needed. The 0.25 mg starting dose is for dose escalation and is not considered a therapeutic maintenance dose.
Common side effects are mostly digestive. In FDA placebo-controlled trials, nausea, vomiting, and diarrhea were more common with Ozempic than placebo; nausea was reported in about 15.8% to 20.3% of patients on Ozempic 0.5–1 mg versus 6.1% on placebo. Vomiting and diarrhea were also more frequent with Ozempic.
Serious warnings matter. Ozempic is contraindicated in people with a personal/family history of medullary thyroid carcinoma or MEN2, and in people with serious hypersensitivity to semaglutide. Labels also warn about possible thyroid C-cell tumors, pancreatitis symptoms, diabetic retinopathy complications in some people with diabetes, severe GI reactions, allergic reactions, and gallbladder disease.
Pregnancy and breastfeeding are important exclusions. The Canadian monograph says Ozempic should not be used during pregnancy or breastfeeding; FDA labeling says to stop Ozempic at least 2 months before a planned pregnancy because semaglutide remains in the body for weeks.
Bottom line: Ozempic is a legitimate, effective medication for many adults with type 2 diabetes, and it often causes weight loss, but it is not a casual slimming drug. The benefits can be significant, but so can the side effects and contraindications, so it should be used with a prescriber’s monitoring.
